Malaria is a major human health-threatening disease, resulting in approximately 300-500 million clinical cases and 1-3 million deaths each year worldwide, mainly among young children (
1). Of the four species of
Plasmodium that transmit human malaria,
Plasmodium falciparum causes the most severe clinical manifestations of the disease and is responsible for most of the malaria morbidity and almost all of its related mortality (
2). Despite enormous efforts to control and prevent malaria, multiple factors, including insecticide resistance in the mosquito vectors, lack of effective vaccines, and the emergence and rapid spread of drug-resistant strains, have been contributing to the global worsening of the malaria situation (
3). Therefore, there is an urgent need for development of effective malaria vaccines (
4).
However, extensive genetic diversity in natural parasites populations is a major blockage for development of an effective vaccine against human malaria parasite, since antigenic diversity limits the efficacy of the acquired protective immunity to malaria (
4-
7). Such extensive antigenic polymorphism intensely improves the parasite ability to invade the host’s immune system, making it difficult to evoke adequate responses against all of the antigenic variants of the parasite population (
8). A true understanding about the frequencies and alterations of vaccine-candidate antigens in natural parasites populations is crucial to design a successful and effective malaria vaccine, as well as providing useful facts for interpretation of responses to the vaccine.
P. falciparum stage-specific antigens have been characterized as vaccine candidates through molecular techniques. We analyzed the genetic diversity of merozoite surface protein 3 (MSP-3) antigen as a potential vaccine candidate.
One of the target antigens for inclusion in a malaria vaccine is
P. falciparum MSP-3. MSP-3 is a nonintegral surface-associated protein that may be an important target for antibody-mediated protective immunity, as truncation of the MSP-3 gene reduces the parasite invasion (
9). Although its function remains unknown, it has been suggested to be involved in erythrocyte binding (
9,
10).
P. falciparum MSP-3 is encoded by a single locus on chromosome 10 of the parasite (
5). MSP-3 is a polymorphic antigen with a number of structural domains (
6,
11). These include three blocks of four-heptads repeats of the type AXXAXXX, a hydrophilic region, and a putative leucine zipper sequence at the C-terminus (
12).
Variations among alleles of MSP-3 occur through substitutions and deletions in nonrepetitive sequences and flanking of the alanine heptad-repeat domains (
13). However, there is significant conservation in parts of the molecule, particularly the alanine residues within the heptad-repeat regions, and the C-terminal half of the protein, which includes the putative leucine zipper region (
14,
15). There are several sequence varieties among MSP-3 alleles, but the sequence polymorphism defines two major allele classes (K1 and 3D7), which show only limited recombination (
16). The majority of both intra- and inter-allele differences are localized in the heptad-repeat region, defining the N-terminal domain (
11). MSP-3 is therefore a strong vaccine candidate with limited epidemiologic data; the data needed to support its continuous development along the proposed malaria vaccine roadmap.
Iran is located in the Eastern Mediterranean region, and grouped as a low-to-moderate endemic region (
17). Sistan and Baluchistan province, southeast of Iran, is the endemic area of
falciparum malaria and considered as its oriental eco-epidemiological region (
18). Malaria cases are reported during the whole year with two peaks, the first with predominant
P. vivax, April through September, and the second with 45% to 50%
P. falciparum infections after September (
19).